Table 8 Predictors of survival in patients suffering from pyogenic liver abscess
From: The role of Enterococcus spp. and multidrug-resistant bacteria causing pyogenic liver abscesses
Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
Variables | OR (95% CI) | P value | OR (95% CI) | P value |
Age | 0.99 (0.95–1.04) | 0.73 | ||
Male gender | 0.86 (0.22–3.38) | 0.83 | ||
Predisposing disease | ||||
Malignancy | 0.22 (0.05–0.93) | 0.04 | 0.19 (0.04–0.94) | 0.041 |
Liver cirrhosis | 0.77 (0.14–4.18) | 0.77 | ||
Diabetes mellitus | 1.38 (0.27–7.19) | 0.70 | ||
Medication | ||||
Proton-pump inhibitor use | 0.68 (0.13–3.52) | 0.64 | ||
Immunosuppression | 0.85 (0.16–4.57) | 0.85 | ||
Blood values | ||||
C-reactive Protein | 1.10 (0.98–1.23) | 0.10 | ||
WBC | 0.98 (0.91–1.06) | 0.56 | ||
Bilirubin | 0.85 (0.75–0.98) | 0.02 | 0.85 (0.75–0.97) | 0.015 |
Creatinine | 0.63 (0.26–1.53) | 0.30 | ||
INR | 0.44 (0.10–1.99) | 0.29 | ||
Cholangitis | 0.19 (0.04–0.98) | 0.046 | ||
MDRO | 0.75 (0.17–3.26) | 0.70 | ||
Mycotic coinfection | 0.41 (0.10–1.67) | 0.22 | ||
Initial empirical antibiotic treatment | ||||
Carbapenem based | 0.60 (0.15–2.33) | 0.46 | ||
Glycopeptide based | 1.12 (0.26–4.79) | 0.88 | ||
Tigecycline based | 0.79 (0.08–7.56) | 0.84 | ||
Metronidazole based | 2.89 (0.33–25.03) | 0.33 | ||